FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157651421> ?p ?o ?g. }

• W3157651421 endingPage "A167" @default.
• W3157651421 startingPage "A166" @default.
• W3157651421 abstract "Abstract Background: The ESE-ENSAT guidelines on the management of adrenocortical carcinoma (ACC) suggest adjuvant mitotane for patients at high risk of recurrence following radical surgery. This indication has a limited evidence base, lacking results from randomized controlled trials. No suggestion for or against adjuvant mitotane in low-risk patients was given, since studies did not stratify patients for prognosis. The randomized controlled study ADIUVO compared the efficacy of adjuvant mitotane treatment vs. observation in prolonging recurrence-free survival (RFS) in ACC patients at low-intermediate risk of recurrence. Methods: The main inclusion criteria were: stage I-III ACC, R0 surgery, and Ki-67 ≤10%. Patients were randomly assigned 1:1 to adjuvant mitotane (MIT) or observation (OBS). The primary endpoint of the study was RFS. Patients who refused randomization were offered inclusion in the ADIUVO OBSERVATIONAL study. In this prospective, observational study, patients were managed as in the ADIUVO study. A total of 91 patients were enrolled in ADIUVO, 45 in the MIT and 46 in the OBS arm. Baseline characteristics of patients were perfectly matched between the 2 arms: median age, 51 vs. 50.5 years; female, 73% vs. 67%; stage I, 20% vs. 26%; stage II, 67% vs. 63%, stage III, 13% vs. 11%; ACC secretion 44% vs. 36%; Weiss 5 vs. 5; respectively. In ADIUVO OBSERVATIONAL, 42 patients were treated with mitotane and 53 were untreated. Baseline characteristics of patients were matched between the 2 groups and with MIT and OBS groups in ADIUVO. Thus, the ADIUVO OBSERVATIONAL cohorts could be analyzed in parallel to those of ADIUVO. Results: In the ADIUVO study, recurrences were 8 in the MIT and 11 in the OBS arm, while deaths were 2 and 5, respectively. RFS and overall survival (OS) did not significantly differ between the 2 arms. Tumor size was a predictor of RFS in multivariable analysis. In the OBS arm, the HR for recurrence was 1.321 (95%CI, 0.55–3.32, p=0.54) and HR for death 2.171 (95%CI, 0.52–12.12, p=0.29). The survival analysis in the ADIUVO OBSERVATIONAL study confirmed the findings of ADIUVO. Given the outcome of both studies, the NNT is 55. Conclusions: ACC patients at low-intermediate risk of recurrence after surgery are a minority; however, they show a far better prognosis than expected (5-year RFS is about 75%) and do not benefit significantly from adjuvant mitotane. The results of the ADIUVO study do not support routine use of adjuvant mitotane in this subset of patients, who may thus avoid a potentially toxic treatment. This is an important step toward personalization of ACC care." @default.
• W3157651421 created "2021-05-10" @default.
• W3157651421 creator A5003946700 @default.
• W3157651421 creator A5004673392 @default.
• W3157651421 creator A5008529320 @default.
• W3157651421 creator A5014771501 @default.
• W3157651421 creator A5016606339 @default.
• W3157651421 creator A5023418111 @default.
• W3157651421 creator A5031848496 @default.
• W3157651421 creator A5034012396 @default.
• W3157651421 creator A5042079657 @default.
• W3157651421 creator A5050015004 @default.
• W3157651421 creator A5050426287 @default.
• W3157651421 creator A5053031594 @default.
• W3157651421 creator A5058896363 @default.
• W3157651421 creator A5061844889 @default.
• W3157651421 creator A5067116958 @default.
• W3157651421 creator A5068628282 @default.
• W3157651421 creator A5073757326 @default.
• W3157651421 creator A5076138289 @default.
• W3157651421 creator A5076459020 @default.
• W3157651421 creator A5077463120 @default.
• W3157651421 creator A5080825844 @default.
• W3157651421 creator A5080828317 @default.
• W3157651421 creator A5083625945 @default.
• W3157651421 creator A5084783349 @default.
• W3157651421 date "2021-05-01" @default.
• W3157651421 modified "2023-10-18" @default.
• W3157651421 title "Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients" @default.
• W3157651421 doi "https://doi.org/10.1210/jendso/bvab048.336" @default.
• W3157651421 hasPublicationYear "2021" @default.
• W3157651421 type Work @default.
• W3157651421 sameAs 3157651421 @default.
• W3157651421 citedByCount "14" @default.
• W3157651421 countsByYear W31576514212021 @default.
• W3157651421 countsByYear W31576514212022 @default.
• W3157651421 countsByYear W31576514212023 @default.
• W3157651421 crossrefType "journal-article" @default.
• W3157651421 hasAuthorship W3157651421A5003946700 @default.
• W3157651421 hasAuthorship W3157651421A5004673392 @default.
• W3157651421 hasAuthorship W3157651421A5008529320 @default.
• W3157651421 hasAuthorship W3157651421A5014771501 @default.
• W3157651421 hasAuthorship W3157651421A5016606339 @default.
• W3157651421 hasAuthorship W3157651421A5023418111 @default.
• W3157651421 hasAuthorship W3157651421A5031848496 @default.
• W3157651421 hasAuthorship W3157651421A5034012396 @default.
• W3157651421 hasAuthorship W3157651421A5042079657 @default.
• W3157651421 hasAuthorship W3157651421A5050015004 @default.
• W3157651421 hasAuthorship W3157651421A5050426287 @default.
• W3157651421 hasAuthorship W3157651421A5053031594 @default.
• W3157651421 hasAuthorship W3157651421A5058896363 @default.
• W3157651421 hasAuthorship W3157651421A5061844889 @default.
• W3157651421 hasAuthorship W3157651421A5067116958 @default.
• W3157651421 hasAuthorship W3157651421A5068628282 @default.
• W3157651421 hasAuthorship W3157651421A5073757326 @default.
• W3157651421 hasAuthorship W3157651421A5076138289 @default.
• W3157651421 hasAuthorship W3157651421A5076459020 @default.
• W3157651421 hasAuthorship W3157651421A5077463120 @default.
• W3157651421 hasAuthorship W3157651421A5080825844 @default.
• W3157651421 hasAuthorship W3157651421A5080828317 @default.
• W3157651421 hasAuthorship W3157651421A5083625945 @default.
• W3157651421 hasAuthorship W3157651421A5084783349 @default.
• W3157651421 hasBestOaLocation W31576514211 @default.
• W3157651421 hasConcept C126322002 @default.
• W3157651421 hasConcept C141071460 @default.
• W3157651421 hasConcept C143998085 @default.
• W3157651421 hasConcept C146357865 @default.
• W3157651421 hasConcept C151730666 @default.
• W3157651421 hasConcept C168563851 @default.
• W3157651421 hasConcept C203092338 @default.
• W3157651421 hasConcept C204243189 @default.
• W3157651421 hasConcept C23131810 @default.
• W3157651421 hasConcept C2776735609 @default.
• W3157651421 hasConcept C2777863537 @default.
• W3157651421 hasConcept C2781399356 @default.
• W3157651421 hasConcept C71924100 @default.
• W3157651421 hasConcept C86803240 @default.
• W3157651421 hasConcept C90924648 @default.
• W3157651421 hasConceptScore W3157651421C126322002 @default.
• W3157651421 hasConceptScore W3157651421C141071460 @default.
• W3157651421 hasConceptScore W3157651421C143998085 @default.
• W3157651421 hasConceptScore W3157651421C146357865 @default.
• W3157651421 hasConceptScore W3157651421C151730666 @default.
• W3157651421 hasConceptScore W3157651421C168563851 @default.
• W3157651421 hasConceptScore W3157651421C203092338 @default.
• W3157651421 hasConceptScore W3157651421C204243189 @default.
• W3157651421 hasConceptScore W3157651421C23131810 @default.
• W3157651421 hasConceptScore W3157651421C2776735609 @default.
• W3157651421 hasConceptScore W3157651421C2777863537 @default.
• W3157651421 hasConceptScore W3157651421C2781399356 @default.
• W3157651421 hasConceptScore W3157651421C71924100 @default.
• W3157651421 hasConceptScore W3157651421C86803240 @default.
• W3157651421 hasConceptScore W3157651421C90924648 @default.
• W3157651421 hasIssue "Supplement_1" @default.
• W3157651421 hasLocation W31576514211 @default.
• W3157651421 hasLocation W31576514212 @default.
• W3157651421 hasOpenAccess W3157651421 @default.
• W3157651421 hasPrimaryLocation W31576514211 @default.

• next